EU Clinical Trial 2017-004752-34

Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study.  Feb 20, 2019

Main objective of the trial: 1. To assess safety and characterize toxicities of pembrolizumab combined with ataluren in patients with pMMR mCRC, dMMR mCRC and dMMR mEC. 2. To determine the immune-related progression free survival (irPFS) rate at 21 weeks and objective response rate (irORR) at 30 weeks in patients with pMMR mCRC, dMMR mCRC and dMMR mEC treated with pembrolizumab combined with ataluren using immune related response criteria (irRC). 1. Beoordelen van de veiligheid en de toxiciteit van Ataluren in combinatie met Pembrolizumab in patienten met pMMR mCRC, dMMR mCRC en dMMR mEC. 2. Immuungerelateerde progressievrije overleving (irPFS) vastellen bij 21 weken en immuun gerelateerde objectieve response rate (irORR) bij 30 weken in patiënten met pMMR mCRC, dMMR mCRC en dMMR mEC, gebruikmakend van immuun gerelateerde respons criteria (irRC)

Parties

Sponsors
Countries
NL
Keywords
ATALUREN Keytruda PEMBROLIZUMAB Translarna

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.